Home › Cytopenia › NCT07081087

Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in Cytopenia Patients

Development of a Peripheral Blood Assay to Replace BM Evaluation in Cytopenia - a Multi-Center Observational Study

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Patients aged 18 and up with suspected/confirmed MDS cases referred to BM evaluation either for diagnosis or risk assessment due to cytopenia
2. Platelets \< 150 × 10E9/L or
3. Absolute neutrophil count \< 1.8 × 10E9/L or
4. Hemoglobin (Hgb) \< 13 g/dL (males) and \< 12 g/dL (female) and
5. For both sexes, no evidence of Iron, folinic acid, or B12 deficiency

Exclusion Criteria:

1. Women who are pregnant
2. Previous diagnosis of leukemia; AML, MPN, ALL, CLL, MGUS/MM or any other gammopathy
3. Lymphocytes \> 5000/ul
4. Patients who are on disease-related therapy are excluded, unless they are treated with Erythropoietin or Prednisone. See Appendix 2 for the list of excluded treatments.
5. Patients who have undergone a bone marrow transplant.

About the study

This observational, multi-center study aims to collect data in order to develop a novel, minimally invasive diagnostic tool for MDS based on peripheral blood profiling of circulating hematopoietic stem and progenitor cells (cHSPCs) using single-cell RNA sequencing and DNA sequencing.

What is being tested

• PERIBLOOD-MDS (diagnostic test)

Sponsor: Weizmann Institute of Science · Participants: 1,500 · Started: Jun 1, 2025

Contact the study team

• Clinical Trial Manage · Phone: +972522666230
• Liran Shlush, Prof. · Phone: +972505109815

Official record on ClinicalTrials.gov — NCT07081087

Locations in the U.S.

Conditions

• Cytopenia

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.